[This paper has been commented by Paras Karmacharya et al. Please read the response here.](http://www.jchimp.net/index.php/jchimp/article/view/29308)

I am writing in regards to an inaccuracy in the recent case report published in the *Journal of Community Hospital Internal Medicine Perspectives* by Karmacharya et al. ([@CIT0001]). The authors had stated that sodium zirconium cyclosilicate (ZS-9) along with patiromer sorbitex calcium (patiromer) has not been studied in patients with serum potassium (K^+^) concentrations \>6.5 mEq/L. However, it should be noted that while it is true that the phase III trial of patiromer did not include patients with serum K^+^ \>6.5 mEq/L, that is not the case with ZS-9. Specifically, we would like to point out that:There was no upper limit of baseline serum K^+^ specified for patient inclusion in the ZS-9 HARMONIZE study ([@CIT0002]).The HARMONIZE study included nine patients with baseline serum K^+^ \>6.5 mEq/L (up to 7.2 mEq/L).The mean baseline serum K^+^ of HARMONIZE study patients was 5.6 mEq/L ([@CIT0002]).A Letter to the Editor published in the *New England Journal of Medicine* described analyses conducted on a combined cohort of 45 patients with baseline serum K^+^ from 6.1 to 7.2 mEq/L from two Phase III ZS-9 studies (ZS003 and HARMONIZE) ([@CIT0003]). The mean baseline serum K^+^ concentration of this combined cohort was 6.3 mEq/L.

With these data in mind, I affirm to the reader that there are published clinical data of ZS-9 treatment achieving normokalemia in patients with baseline serum K^+^ \>6.5 mEq/L.
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